Table 1.
Clinical characteristics of the CD patients and control subjects.
| Crohn's disease (n = 60) | Control (n = 32) | P | |
|---|---|---|---|
| Age (years) | 27 (20.25, 31.50) | 30 (23, 41.5) | 0.160 |
| Gender | |||
| Female | 13 | 12 | 0.140 |
| Male | 47 | 20 | |
| Disease duration (months) | 30.45 (3.20, 188.10) | ||
| Age at diagnosis | |||
| A1 (<16 years) | 6 | — | |
| A2 (16~40 years) | 48 | — | |
| A3 (>40 years) | 6 | — | |
| Disease location | |||
| L1 (ileum) | 21 | — | |
| L2 (colon) | 6 | — | |
| L3 (ileum-colon) | 33 | — | |
| L4 (upper gastrointestinal tract) | 2 | — | |
| Disease behavior | |||
| B1 (nonstenotic, nonpenetrating) | 34 | — | |
| B2 (stenotic) | 22 | — | |
| B3 (penetrating) | 4 | — | |
| p (perianal) | 25 | — | |
| Serum IL-27 level (pg/ml) | 110.0 (95.0, 145.0) | 85.0 (80.0, 95.0) | <0.001 |
| Serum IL-23 level (pg/ml) | 23.7 (16.2, 35.9) | 20.6 (14.4, 23.6) | 0.162 |
| Medical therapy | |||
| Mesalazine only | 14 | ||
| Steroids±mesalazine | 14 | ||
| Azathioprine±mesalazine | 8 | ||
| Infliximab±mesalazine | 35 |
Values are expressed as median (interquartile range (IQR)).